Posted by Michael Wonder on 29 Sep 2021
FDA expands Lilly's Erbitux (cetuximab) label with combination of Braftovi (encorafenib) for the treatment of BRAF V600E mutation positive metastatic colorectal cancer after prior therapy
28 September 2021 - Erbitux is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for adults with previously treated metastatic colorectal cancer with a BRAF V600E mutation.
Eli Lilly today announced that the U.S. FDA has granted approval of a new indication for Erbitux (cetuximab) in combination with Braftovi (encorafenib), marketed by Pfizer, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA approved test, after prior therapy.
